Semaglutide
60 articles on Semaglutide, written by Shotlee and medically reviewed for clinical accuracy.
RFK Jr. and the Perils of Unapproved Peptides
The mantra 'once an accident, twice a coincidence, three times a trend' fuels bad journalism—and worse, risky medicine. A New Yorker investigation exposes clinics pushing unproven peptides for healing and longevity, backed by RFK Jr. While semaglutide proves the exception, most lack evidence and pose real harms.
5 min read
Generic Ozempic Semaglutide Gets Tentative USFDA Approval; OneSource CDMO Par...
A generic version of Ozempic semaglutide has received tentative USFDA approval, marking a key step toward affordable GLP-1 therapy. Orbicular spearheaded product development, partnering with OneSource Specialty Pharma as the CDMO for reliable U.S. market manufacturing. This collaboration promises steady commercial supply from an FDA-approved site.
5 min read
How to Keep Weight Off After Ozempic: Proven Strategies
Stopping Ozempic often leads to weight regain—up to 7% in trials or two-thirds within a year. While continuing semaglutide helps sustain losses, lifestyle changes and maintenance dosing offer alternatives. Work with your healthcare team for a personalized plan to keep the weight off long-term.
6 min read
Indian Companies Rush to Make Generic GLP-1s Like Semaglutide
India's pharma giants are in a fierce race to develop generic GLP-1 drugs like semaglutide following its patent expiry, amid soaring obesity rates affecting nearly a third of adults. One executive dubbed it a 'bloodbath' as demand surges. Eli Lilly's CEO highlighted oral pills as a key solution to global supply shortages.
4 min read
Generic Semaglutide Share Rises to 33% in 10 Days, Boosting Torrent, Dr. Redd...
The launch of generic Semaglutide in India has rapidly captured 33% market share within just 10 days, according to CLSA's channel checks, primarily benefiting Torrent Pharmaceuticals, Dr. Reddy's Laboratories, and Zydus Lifesciences. This surge has dented Eli Lilly's Mounjaro share from 61% to 56%. As generics make GLP-1 therapies more accessible, what does this mean for patients with type 2 diabetes and obesity?
5 min read
Popular Weight Loss Drugs May Cause Hidden Muscle Loss, Study Finds
Popular drugs like semaglutide and tirzepatide are transforming weight loss for type 2 diabetes and obesity patients. But a new UNC study warns of hidden muscle loss that could impact strength and mobility. Here's what the research means for safe, healthy weight management.
5 min read
Social Media Reveals GLP-1 Side Effects Missed in Clinical Trials
Social media is spotlighting GLP-1 receptor agonist side effects that clinical trials overlooked, according to a new study in Nature Health. Researchers sifted through 410,198 Reddit posts on semaglutide and tirzepatide, finding 43.5% of users reporting issues like nausea and fatigue. These insights reveal patient concerns beyond traditional data.
4 min read
MSN Labs Launches Semabest: Generic Semaglutide in India
MSN Laboratories has launched Semabest, its affordable generic version of semaglutide, in the Indian market after CDSCO approval. Priced nearly 50% lower than the branded drug and available in pre-filled pens, it promises comparable efficacy in HbA1c reduction, glucose control, and weight loss. This move aims to address India's diabetes crisis affecting 90 million people.
5 min read
Ozempic Improves Liver Health Without Weight Loss, Study Finds
A groundbreaking study shows that Ozempic and Wegovy enhance liver health directly, bypassing the need for weight loss. Canadian researchers uncovered semaglutide's action on key liver cells, challenging old assumptions about GLP-1 therapies. This could transform care for metabolic liver diseases like MASH.
6 min read
Ozempic Isn't a Magic Fix: Semaglutide Risks in India
Semaglutide injections like Ozempic have arrived in India at low prices, exciting millions with diabetes and rising obesity. But experts like Dr. Gagandeep Singh caution it's no magic fix—weight returns upon stopping, muscle loss is common, and misuse risks malnutrition. Understand the real story behind these GLP-1 weight loss injections.
6 min read
Study: Semaglutide Does Not Raise NAION Risk in Obesity, Diabetes
A large study presented in San Diego reveals semaglutide use is not associated with higher risk of non-arteritic anterior ischemic optic neuropathy (NAION) in patients with overweight or obesity. In fact, it lowered NAION risk by 64% among those with type 2 diabetes compared to non-GLP-1 therapies. Experts emphasize continued monitoring of blood sugar and blood pressure.
5 min read
50 Brands Target India's Post-Patent Semaglutide Market
India's semaglutide market is heating up with more than 50 brands poised to launch post-patent. But experts warn of a measured rollout due to the drug's intricate manufacturing demands. Inside the scramble for affordable GLP-1 access in a diabetes hotspot.
5 min read
Cheaper Generic Semaglutide in India: Experts Warn Against Quick-Fix Use
Cheaper generic semaglutide is transforming access to weight loss and diabetes treatment in India, priced at just Rs750 per weekly injection. However, experts caution against 'quick-fix' use without medical oversight, highlighting risks like 40% muscle loss from lean mass. Discover clinical evidence from STEP-1 and SELECT trials and why structured care is essential.
5 min read
Ozempic Hair Loss: Doctors Explain the Real Causes
Ozempic users are reporting more hair in brushes and showers, sparking fears of direct drug damage. But doctors like bariatric surgeon Dr. Neha Shah explain it's mainly from rapid weight loss triggering telogen effluvium. With proper nutrition and care, most see full recovery within months.
5 min read
Emcure Revises Poviztra Semaglutide Price to ₹3,999/Month in India
Emcure Pharmaceuticals is slashing the price of Poviztra semaglutide injection to ₹3,999 per month starting April 3, 2026, making this weight management therapy more accessible across India. As the first Indian firm offering this second brand of Novo Nordisk's semaglutide, Emcure aims to tackle the nation's obesity epidemic affecting over 600 million adults. Backed by 49 million patient years and 50 clinical trials, Poviztra promises validated support for obesity-linked conditions.
5 min read
Emcure Halves Poviztra Semaglutide Price After Novo Nordisk Patent Expiry
Emcure Pharmaceuticals has halved the price of its semaglutide-based weight loss drug Poviztra after the expiry of Novo Nordisk's patent, making GLP-1 therapy more accessible. Originally developed for diabetes, semaglutide mimics hormones to control appetite and blood sugar, delivering unmatched weight loss results. Check the new rates and learn what this means for patients seeking effective metabolic treatments.
4 min read
Emcure Drops Poviztra Semaglutide Starting Dose Price by 55%
Emcure Pharmaceuticals has reduced the price of its semaglutide injection Poviztra by 55% for the starting dose, now at ₹3,999 per month. This move, in partnership with Novo Nordisk, follows recent price slashes on Wegovy and Ozempic and the launch of Indian generics. It aims to tackle India's growing obesity epidemic affecting over 600 million adults.
5 min read
Wegovy's New Subscription Saves Up to $1,200/Year – Not for Everyone
Novo Nordisk has launched a new subscription program for Wegovy, promising up to $1,200 in yearly savings on injections to help patients maintain access to this GLP-1 obesity drug. With plans starting at $249 per month for 12 months, it targets self-pay users facing cost uncertainty. But eligibility limits mean it's not for everyone—here's what you need to know.
4 min read
FDA Approves Triple Max Dose of Wegovy: 7.2mg Now Available
The FDA just greenlit a groundbreaking higher dose of Wegovy, tripling the previous maximum to 7.2 milligrams for enhanced weight management. Patients saw up to 21% body weight loss, with unique cardiovascular protections. Here's what this means for obesity treatment and access.
5 min read
Novo Nordisk Bets on Clinical Depth vs Discounts for Semaglutide Generics in ...
After semaglutide's patent expired on March 20, over 40 Indian manufacturers launched 50+ generics, slashing prices up to 90%. Novo Nordisk, maker of Ozempic and Wegovy, is countering not with deep discounts but clinical data from 50+ trials and partnerships. Vikrant Shrotriya shares how this strategy aims to widen access while preserving quality.
5 min read
India Cracks Down on GLP-1 Drug Misuse Amid Generic Surge
India's government is ramping up enforcement against GLP-1 drug misuse following a flood of cheap semaglutide generics. Inspections at 49 pharmacies, wholesalers, and clinics uncovered unauthorized sales and misleading marketing. With sales surging 177%, regulators warn of health risks without medical supervision.
5 min read
Experts Stress Holistic Approach to Semaglutide for Weight Management
At a recent Pune meeting, experts from Pune and Mumbai underscored a holistic framework for Semaglutide use in weight management, especially as the drug goes off-patent in India. They stress pairing it with diet, exercise, and thorough patient assessments for lasting results in obesity and diabetes control. Generic versions now available for Rs 1,290 per month offer affordable access with proper precautions.
6 min read
Telangana Warns on Semaglutide Misuse for Weight Loss
Telangana's Drugs Control Administration has issued a stark warning against misusing Semaglutide formulations for weight loss without medical oversight. With patent expiry looming in March 2026, multiple versions are flooding the market, raising safety concerns. Improper use risks serious complications like pancreatitis and gastrointestinal disorders.
5 min read
Alkem Launches Affordable Semaglutide Injection in India at Rs450 Weekly
Alkem Laboratories is revolutionizing GLP-1 access in India with its new semaglutide injection, priced at just Rs450 per week. Branded as Semasize, Obesema, and Hepaglide, this once-weekly therapy targets Type 2 diabetes and chronic weight management. Learn about its approvals, innovative pens, and potential impact on affordable care.
5 min read
Semaglutide Prices Drop 70-90% in India After Generic Launches by Sun Pharma,...
Semaglutide prices in India have plummeted by up to 90% following the launch of over 15 generic versions just days after patent expiry. Major players like Sun Pharma, Zydus Lifesciences, Dr Reddy's, and Natco are offering affordable options for type 2 diabetes and obesity management. This shift promises greater access to this vital GLP-1 agonist therapy.
6 min read
Study: 10% of Wegovy and Ozempic Users See Minimal Weight Loss
Recent trials show about 10% of people using Wegovy and Ozempic experience minimal weight loss, classified as 'non-responders.' Despite average reductions of 15-20%, stories like Samantha Jess's highlight real challenges. Discover why GLP-1 drugs don't work for everyone and how to optimize results.
5 min read
Grim Effects of Stopping GLP-1s Like Ozempic, Study Finds
New research paints a stark picture: stopping GLP-1 drugs like Ozempic can rapidly reverse cardiovascular benefits, with risks spiking 8% after just six months. Published in BMJ Medicine, the study tracked over 333,000 adults and warns of 'metabolic whiplash.' Patients face weight regain, inflammation resurgence, and lasting scars from interruptions.
4 min read
Safety Signals Matter as Semaglutide Scales in India
Semaglutide's patent expiry in India has flooded the market with affordable generics, dropping prices from over ₹10,000 to as low as ₹1,300 per month. While this opens access for millions with Type 2 diabetes and obesity, experts warn of safety risks from misuse without proper guidance. Discover the implications for patients and the growing market.
5 min read
Grim Effects of Stopping GLP-1s Like Ozempic, Study Reveals
New research paints a grim picture: stopping GLP-1 drugs like Ozempic can rapidly reverse cardiovascular benefits, with risks spiking 8% after just six months. A Washington University study of over 333,000 patients highlights the 'metabolic whiplash' of discontinuation. Understand the findings and why adherence matters.
5 min read
New Fitness Classes for Ozempic Users at Oxford Leisure Centres
Oxford leisure centres have launched tailored fitness classes for people on Ozempic and other GLP-1 medications like semaglutide. Operated by Leisure Solutions Community Trust, the program provides specialist instructors to help users lose weight safely while preserving muscle mass. Councillor Chewe Munkonge praises it for aiding health goals.
5 min read
Ozempic Cuts Depression, Anxiety, and Addiction Risk: Study
A groundbreaking study reveals that Ozempic and other GLP-1 medications like semaglutide significantly lower risks of depression, anxiety, addiction, and even suicidal behavior. Analyzing nearly 100,000 people, researchers found up to 47% reductions in related hospital visits and work absences. This could transform treatment for those with overlapping metabolic and mental health issues.
5 min read
Natco Pharma Starts Semaglutide Price War: Generic at ₹1,290/Month, 90% Cheaper
Natco Pharma is shaking up India's weight-loss drug market with its generic semaglutide priced at just ₹1,290 per month—90% cheaper than Novo Nordisk's Ozempic. Launching Saturday after patent expiry, this move invites competition from Sun Pharma, Dr Reddy's, and others. Patients gain affordable access to this GLP-1 powerhouse for weight management and diabetes.
5 min read
Ozempic and Wegovy Linked to Reduced Anxiety and Depression Risk
Semaglutide, the active ingredient in Ozempic and Wegovy, is associated with a 44% decreased risk of worsening depression and 38% lower anxiety risk, per a large Swedish study. Researchers suggest potential neurobiological effects beyond weight loss. Discover how these GLP-1 agonists may support mental health in diabetes and obesity patients.
5 min read
Semaglutide Generics Set for One-Fourth Price After Patent Expiry
Semaglutide prices in India are poised for a dramatic drop to one-fourth of current levels following patent expiry on March 20. Generics from seven companies like Sun Pharma and Zydus Lifesciences will make Ozempic and Wegovy alternatives more accessible for diabetes and obesity management. Experts highlight improved adherence but warn of misuse risks.
5 min read
Zydus, Lupin Partner to Launch Ozempic Rival Semaglutide in India
Zydus Lifesciences and Lupin are teaming up to bring Semaglutide injection to India, positioning it as a rival to Ozempic for type 2 diabetes and chronic weight management. Marketed by Zydus with a user-friendly reusable pen, this GLP-1 therapy offers new options for adults with poor glycemic control or obesity-related conditions. Here's what patients need to know about this launch.
5 min read
Study: Wegovy Vision Loss Risk 5x Higher Than Ozempic
A groundbreaking study reveals Wegovy carries a fivefold higher risk of vision-threatening ischemic optic neuropathy compared to Ozempic. Analyzing millions of FDA reports, researchers link the risk to semaglutide's higher doses in Wegovy. Amid rising lawsuits, patients need to weigh benefits against potential eye health dangers.
5 min read
GLP-1 Persistence for Weight Loss Nearly Doubles in Recent Years
Persistence rates for GLP-1 medications like semaglutide and tirzepatide in patients without diabetes seeking weight loss have nearly doubled over the past five years, jumping from 33.2% in 2021 to 60.9% in mid-2024. New research highlights improved adherence, the role of drug switching, and factors like resolved supply shortages driving these gains. These trends offer hope for long-term obesity management.
5 min read
Study: Ozempic-Type Drugs Like Semaglutide Can Be Made for $3/Month
A groundbreaking study shows blockbuster drugs like Ozempic and Wegovy could be manufactured at a fraction of their retail cost, potentially revolutionizing access to obesity and diabetes care. Researchers estimate semaglutide production at $3 per month for injectables, compared to hundreds today. This comes amid rising obesity in low-income countries, though experts stress lifestyle factors remain key.
4 min read
Semaglutide Could Cost as Little as $28/Year by End of 2026
Semaglutide, the powerhouse behind Ozempic and Wegovy, might soon become dramatically more affordable. A recent study reveals generic versions could cost as little as $28 per person-year after patents expire in 2026. This could transform access to treatment for obesity and type 2 diabetes globally.
5 min read
The Himsification of Medicine: Super Bowl Ad & Semaglutide Clash
Hims & Hers made waves with a Super Bowl ad promoting preventive care through tailored prescriptions and peptides for everyday Americans. But announcing compounded oral semaglutide triggered an FDA investigation and a swift lawsuit from Novo Nordisk. The quick settlement highlights battles over GLP-1 access and drug pricing.
4 min read
Healthier Happy Selects CoreAge Rx as Top Tirzepatide Online Destination
Independent health platform Healthier Happy has chosen CoreAge Rx as its preferred destination for tirzepatide online, highlighting its physician-supervised telehealth model, straightforward pricing, and direct-to-home delivery. This recognition underscores CoreAge Rx's role in simplifying access to GLP-1 therapies like tirzepatide and semaglutide for metabolic health.
5 min read
90 Day Fiancé's Kim Menzies: 70-lb Weight Loss with Semaglutide
90 Day Fiancé's Kim Menzies has transformed her life, shedding 70 pounds with Semaglutide and embracing newfound confidence. From 260 to 190 pounds, she's sharing her journey of healthier habits and self-love. 'I used to despise shopping for clothes and now I love it!'
6 min read
Hims & Hers, Novo Nordisk End Lawsuit, Collaborate on Wegovy Sales
In a surprise turn, Novo Nordisk is dropping its lawsuit against Hims & Hers Health, paving the way for branded Wegovy and Ozempic sales on the telehealth platform. This follows Hims' brief plan for cheaper compounded versions and FDA warnings on shortages. Patients gain better access to approved GLP-1 medications.
5 min read
What Happens After Stopping GLP-1 Drugs Like Ozempic? UK Study Findings
A new Cambridge study reveals that after stopping GLP-1 drugs like Ozempic and Wegovy, patients regain nearly 60% of lost weight within a year, with appetite returning rapidly. Researchers modeled long-term trends showing about 75% regain over time, emphasizing the need for lifestyle support. This comprehensive guide breaks down the findings and what they mean for patients.
6 min read
Study: GLP-1 Drugs May Fight Addiction Across Major Substances
Patients on GLP-1 drugs like Ozempic report losing interest in cigarettes, alcohol, and more without effort. A physician-led study of over 600,000 VA patients reveals these medications cut addiction-related deaths by 50% and prevent new substance use disorders. This could transform treatment for alcohol, opioids, cocaine, cannabis, and nicotine.
5 min read
Semaglutide Production Cost: $3/Month Could Expand Access to Obesity & Diabet...
A new analysis shows semaglutide, the key ingredient in Ozempic and Wegovy, can be produced for just $3 per month. As patents expire in countries like Brazil, China, and India, generics could dramatically boost access to obesity and diabetes treatments worldwide. This development offers hope amid rising global rates of these conditions.
5 min read
Aspen Pharmacare Targets Semaglutide Generic Approval in Canada by September
Aspen Pharmacare Holdings Ltd. is aiming for regulatory approval of its copycat semaglutide version in Canada by September, positioning itself as a first-mover. CEO Stephen Saad shared this timeline in a recent interview, highlighting Canada's role as a benchmark for other nations. This development could enhance affordability of GLP-1 therapies like Ozempic.
5 min read
Semaglutide Could Slash Heart Tissue Damage Risk After Attack
Weight-loss injections like Ozempic and Wegovy, containing semaglutide, may protect the heart from severe tissue damage after a heart attack, according to new research. The study reveals how this GLP-1 medication prevents the dangerous 'no-reflow' phenomenon. Experts suggest it could even be administered by paramedics en route to the hospital.
5 min read
GLP-1s Curb Cravings Beyond Food: 600K Study Suggests
Patients on GLP-1 drugs report losing cravings not just for food, but for cigarettes, alcohol, and more—without effort. A new study of over 600,000 people confirms dramatic reductions in overdoses, deaths, and new addictions. Could semaglutide and tirzepatide redefine addiction care?
5 min read
GLP-1 Medications Like Ozempic May Cause Hair Loss: Here's Why
Social media is buzzing with reports of hair loss among GLP-1 users on drugs like Ozempic and Wegovy. While research is emerging, experts like Yale dermatologist Dr. Sara Perkins confirm patients are noticing more shedding. Here's the science behind it and steps to address it.
6 min read
Glenmark to Launch Affordable Semaglutide, Joining Indian Peers
Glenmark Pharmaceuticals is gearing up to launch affordable versions of semaglutide, the blockbuster GLP-1 drug for diabetes and obesity, later this month. This move intensifies competition among Indian drugmakers like Sun Pharma and Dr Reddy's following the March 21 patent expiry. With prices potentially half those of innovators, millions of patients stand to gain better access.
5 min read
Semaglutide May Double nAMD Risk in Older Adults: Study
New research from the University of Toronto reveals that older adults with diabetes taking semaglutide (Ozempic and Wegovy) face more than double the risk of neovascular age-related macular degeneration (nAMD), a severe form of vision loss. The study, published in JAMA Ophthalmology, highlights increased risks with longer use and certain comorbidities. Patients should prioritize regular eye exams to catch issues early.
5 min read
Abbott Partners with Novo for Semaglutide Extensior in India
Abbott has tied up with Novo Nordisk India to commercialize Extensior, the second brand of semaglutide injection following Ozempic's launch. This move positions Abbott as the second firm with sole distribution rights for Novo's semaglutide portfolio in India, after Emcure Pharma. With demand surging and generics on the horizon, here's what it means for patients.
4 min read
Abbott Launches Extensior as Second Ozempic Brand in India
Abbott is now marketing Extensior, a second brand of Novo Nordisk's Ozempic, for type 2 diabetes management in India. This partnership comes as the semaglutide patent nears expiry, potentially lowering prices. With proven benefits in HbA1c control, weight loss, and cardiovascular risk reduction, it expands access in a country with over 100 million diabetes cases.
5 min read
Zydus Launches Affordable Semaglutide Brands in India on Patent Expiry
Zydus Lifesciences is set to launch affordable semaglutide injections in India right on patent expiry, targeting the growing Type 2 diabetes and obesity crisis. With innovative reusable pens under brands like SEMAGLYN, MASHEMA, and ALTERME, the company aims to cut costs and improve patient adherence. This move could transform access to GLP-1 therapy for millions.
6 min read
Ozempic-Like Drugs in India May Drop 50% in Price from March 2026
Semaglutide-based weight-loss drugs like Ozempic and Wegovy are set for a price revolution in India, with generics launching after patent expiry on March 20, 2026, potentially halving costs. Domestic giants like Sun Pharmaceutical and Dr. Reddy's are gearing up to make these GLP-1 therapies more affordable amid rising obesity rates. This shift could transform access to effective treatments for diabetes and weight management.
5 min read
Zydus Launches Semaglutide in Reusable Pen After Patent Expiry: Prices to Fall
Zydus Lifesciences is set to revolutionize semaglutide access in India with a reusable adjustable pen device after the patent expires on March 20. Brands like SEMAGLYN™, MASHEMA™, and ALTERMET™ promise easier dosing and lower prices around ₹3,500-4,000 per month. This move could expand GLP-1 therapy for Type 2 diabetes and obesity amid rising demand.
5 min read
GLP-1 Drugs May Treat Rare Genetic Obesity, Japanese Study Finds
A new Japanese study reveals that three popular GLP-1 drugs—semaglutide, tirzepatide, and retatrutide—may offer hope for rare genetic obesity linked to MC4R deficiency. In mice models, these drugs led to significant weight loss despite faulty hunger signals. Experts discuss the potential and limitations for human treatment.
5 min read
Eris Lifesciences Partners Natco for Semaglutide in India
Eris Lifesciences has partnered with Natco Pharma to bring semaglutide, a key GLP-1 receptor agonist, to the Indian market for Type 2 diabetes management. With CDSCO approval secured, the launch is set for March 2026. This move strengthens Eris's diabetes portfolio amid rising diabetes cases in India.
5 min read
US May Fine Hims for Brief Wegovy Compounded Launch
Hims & Hers briefly launched a $49 compounded version of Novo Nordisk's Wegovy, prompting swift FDA backlash and a DOJ referral. Experts say the US could impose fines or injunctions for violating drug laws, though Hims' quick retreat might limit action. This highlights tensions between compounded GLP-1s and approved weight-loss drugs amid surging demand.
5 min read